ArticleJTO clinical and research reports2026

Trastuzumab Deruxtecan Induces Complete Pathological Response in Oligometastatic HER2-Mutant NSCLC: Case Report.

Laurenz Nagl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.